Active substanceSodium deoxyribonucleateSodium deoxyribonucleate Similar drugsTo uncover Deoxynate® solution locally externally FARMZASCHITA NPC, FSUE Russia Derinat® solution locally externally FarmPack, LLC Russia Derinat® solution w / m FarmPack, LLC Russia Ridostin solution w / m in / skin DIAPHARM, LLC Russia Dosage form: & nbspLyophilizate for the preparation of solution for intramuscular and subcutaneous injection. Composition:RNA double-spiral sodium salt - 5 mg,Auxiliary substance (sodium chloride) - 3 mg. Description:Lyophilized porous mass of white color, hygroscopic. Pharmacotherapeutic group:Immunostimulating agent ATX: & nbspL.03.A.X Other immunostimulants Pharmacodynamics:Ridostin is an inducer of interferon, the active principle of which double-stranded RNA upon induction induces the formation of endogenous interferons: leukocyte (alpha-inf), fibroblast (beta-Inf) and immunogenic (gamma-Inf), which at the intracellular level inhibit the reproduction of viruses and the development of intracellular microorganisms (chlamydia, etc.) and thus interfere with the development of the infectious process. Ridostin at the systemic level stimulates the phagocytosis of neutrophils and macrophages, has antiviral, anti-chlamydial properties, acts on the T and B cells, activates natural killers, increases resistance to infections.Ridostin is an early-type inducer with a maximum production of interferon 2-6 hours after administration and return to background values for 2 days.With the application of ridostin in therapeutic doses, its good tolerability is shown, its sensitizing, mutagenic, cumulative and local irritant properties are absent. The drug does not have teratogenic properties and does not have an effect on reproductive function. Pharmacokinetics:With intramuscular route of administration, ridostin is rapidly absorbed, its maximum concentration in the blood is observed after 15 minutes. An hour after the administration, the drug is found in liver and kidney tissues (less than 10%); by the end of the first day, small amounts (2-3%) - in the gastrointestinal tract and skin. Ridostin does not penetrate the blood-brain barrier. The main amount of the drug (about 70%) is excreted from the blood within 4 hours after the administration, mainly with urine. Indications:Prevention and treatment of influenza, acute respiratory viral infections, infectious and inflammatory diseases caused by viruses of simple, genital, herpes zoster and chlamydia. Contraindications:Individual intolerance, pregnancy, severe liver and kidney disease, children under 7 years. Dosing and Administration:Ridostin is administered parenterally (intramuscularly or subcutaneously). Before use, the contents of the ampoule (8 mg) are dissolved in 2 ml of a 0.5% sterile solution of procaine or water for injection.- for the prevention and treatment of influenza and ARVI in children (from 7 years old) and adults, ridostin at a dose of 8 mg dissolved in 1 ml of 0.5% solution of procaine, is administered intramuscularly on the day of treatment of the patient to the doctor. The second administration of the drug is carried out after 2 days, provided that fever, intoxication and risk of exacerbation of chronic inflammatory diseases of the upper respiratory tract and bronchi continue;- with simple, genital and herpes zoster ridostin is administered intramuscularly at a dose of 8 mg once every 3 days. For treatment 3 injections;- with infectious urogenital diseases Ridostine is administered at a dose of 8 mg once every 2 days. For the course of treatment - 4 injections. To prevent recurrence and at the time of relapse, 4 injections of the drug are prescribed at intervals of 2 days. If necessary, the course of treatment is repeated after 2-3 months. Side effects:In rare cases, there is an increase in temperature Overdose:The administration of a dose 40 times higher than the therapeutic dose can cause minor circulatory disturbances in the intestine and kidneys, cause the development of a mild leuco- and lymphopenic reaction, influence the level of metabolic processes (a slight change in the ratios of protein blood fractions, increase in creatinine level, alkaline phosphatase, in the reduction of cholinesterase activity in the blood). These violations are short-term, reversible and do not require additional pharmacological correction measures. Recovery can be accelerated by conducting a diuretic (furosemide) or infusion detoxification therapy. Interaction:Interactions with other drugs are not found. Form release / dosage:Lyophilizate for the preparation of solution for intramuscular and subcutaneous injection. Packaging:For 8 mg (5 mg of active ingredient) in ampoules or glass vials. For 10 ampoules or vials with instructions for use and scarifier in cardboard boxes or 4; 5 ampoules (bottles) in boxes from PS or PVC with instructions for use and scarifier. Storage conditions:At temperatures from minus 12 0C to plus 8 0C, out of reach of children. Shelf life:2 years.Do not use after the expiry date indicated on the ampoule / vial and on the package. Terms of leave from pharmacies:On prescription Registration number:LS-000381 Date of registration:03.08.2010 Expiration Date:Unlimited The owner of the registration certificate:DIAPHARM, LLC DIAPHARM, LLC Russia Manufacturer: & nbspDIAPHARM, LLC Russia Information update date: & nbsp22.08.2015 Illustrated instructions × Illustrated instructions Instructions